Protara's experimental bladder cancer drug shows encouraging results

Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...
Fierce Biotech

Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...
Medindia

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...
Asianet Newsable on MSN

Does TARA stock’s 15% after-hours slump signal a bargain after new bladder cancer data?

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in ...

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...